Bearish Monday For Marijuana Stocks - Flower One Hldgs, SOL Glb Inv Among Top Gainers
Heritage Cannabis Holding shares closed up up at $. Cronos Group shares closed down in the last day. The company's stock closed up in the previous day. Other companies with a focus on the cannabis industry also closed down in the past week.
Benzinga · 1d ago
Weekly Report: what happened at CRBP last week (0513-0517)?
Weekly Report · 1d ago
Analysts’ Top Healthcare Picks: Praxis Precision Medicines (PRAX), Corbus Pharmaceuticals (CRBP)
TipRanks · 1d ago
Google DeepMind CEO: ‘This Is the Next $100 Billion AI Business’
NASDAQ · 4d ago
Cannabis Stock Gainers And Losers From May 16, 2024
Flower One shares closed up at $1e-05. Aurora Cannabis and Canopy Gwth share prices closed up. Cronos Group shares closed down in the last week. The company's shares are down in the past month. The shares of several other companies closed down.
Benzinga · 5d ago
Attention Biotech Investors - Stocks To Watch
RBC’s Healthcare Desk Sector Strategist gauged biotech investor sentiment at the RBC Global Healthcare Conference. Chris McCarthy says biotech investors are focused on the upcoming binary catalysts. McCarthy highlighted some companies that have upcoming data readouts. He says investors should start focusing on these companies as the readouts approach.
Benzinga · 5d ago
Corbus Pharmaceuticals a new outperform at RBC on cancer, obesity assets
Corbus Pharmaceuticals a new outperform at RBC on cancer, obesity assets. The firm has a $77 price target for the company. RBC Capital Markets has initiated Corbus Pharmaceutical's at outperform. The company has a potential alternative or combination candidate to GLP-1 weight loss therapies.
Seeking Alpha · 05/13 17:24
Corbus Pharmaceuticals Initiated at Outperform by RBC Capital
Dow Jones · 05/13 11:34
Corbus Pharmaceuticals Price Target Announced at $77.00/Share by RBC Capital
Dow Jones · 05/13 11:34
RBC Capital Initiates Coverage On Corbus Pharmaceuticals with Outperform Rating, Announces Price Target of $77
Benzinga · 05/13 11:24
Weekly Report: what happened at CRBP last week (0506-0510)?
Weekly Report · 05/13 10:46
Stocks Climb on Lower Bond Yields and Positive Corporate News
US stocks this morning are slightly higher on lower bond yields and positive corporate news. Incyte Corp is up more than +7% after board approves share repurchase authorization of $2 billion. European government bond yields today are lower. The markets will focus on this week's US PPI and CPI reports. Apple is up +1% after reports the company is closing in on an agreement to use OpenAI's technology.
Barchart · 05/13 09:00
Reuters · 05/13 06:41
Cannabis Stock Movers For May 8, 2024
Shares of Khiron Life Sciences (OTC:KHRNF) closed up 99.00%. Affinor Growers shares closed up 18.15% at $0.08. Aurora Cannabis shares closed down 3.15%. The Flowr (OTc:FLWPF) shares also closed down.
Benzinga · 05/08 20:30
Corbus Pharmaceuticals Currently Up Nine Consecutive Days, on Track for Record Winning Streak -- Data Talk
Corbus Pharmaceuticals Holdings Inc (CRBP) is currently at $40.78, up $1.01 or 2.55%. Up nine consecutive days; up 21.75% over this period --Longest winning streak on record. Up 575.25% year-to-date; down 94.56% from its all-time high of $750.
Dow Jones · 05/08 18:52
Corbus Pharmaceuticals Price Target Raised to $60.00/Share From $58.00 by Oppenheimer
Dow Jones · 05/08 16:04
Corbus Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Dow Jones · 05/08 16:04
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $60
Benzinga · 05/08 15:54
Reuters · 05/08 12:11
U.S. RESEARCH ROUNDUP- Adtran Holdings, McKesson, Waters Corp
Wall Street analysts revise ratings and price targets on several U.S.-listed companies. Adtran Holdings, McKesson and Waters Corp among companies with revised targets. Analysts raise their ratings and target prices on several companies on Wednesday. Some of the companies include Arista Networks, Air Transport Services Group and Allegiant Travel.
Reuters · 05/08 06:52
Webull provides a variety of real-time CRBP stock news. You can receive the latest news about Corbus Pharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About CRBP
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco. The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities.